share_log

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Gibson Christopher

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Gibson Christopher

Recursion Pharmaceuticals | 4:持股變動聲明-高管 Gibson Christopher
美股SEC公告 ·  08/29 16:26
Moomoo AI 已提取核心訊息
Christopher Gibson, CEO of Recursion Pharmaceuticals, has engaged in a stock purchase transaction for the company's shares. On August 29, 2024, Gibson acquired 5,000 shares of Recursion Pharmaceuticals' Class A Common Stock at a price of $2.48 per share. This transaction is part of an exercise or conversion of a derivative security. Following this acquisition, Gibson's direct holdings in the company increased to a total of 757,656 shares. The transaction is currently in progress.
Christopher Gibson, CEO of Recursion Pharmaceuticals, has engaged in a stock purchase transaction for the company's shares. On August 29, 2024, Gibson acquired 5,000 shares of Recursion Pharmaceuticals' Class A Common Stock at a price of $2.48 per share. This transaction is part of an exercise or conversion of a derivative security. Following this acquisition, Gibson's direct holdings in the company increased to a total of 757,656 shares. The transaction is currently in progress.
Recursion Pharmaceuticals的CEO Christopher Gibson參與了一項公司股票購買交易。2024年8月29日,Gibson以每股2.48美元的價格購買了5,000股Recursion Pharmaceuticals的A類普通股。此次交易是衍生證券的行權或轉換的一部分。在此次收購之後,Gibson在公司的直接持股增加到總共757,656股。該交易目前正在進行中。
Recursion Pharmaceuticals的CEO Christopher Gibson參與了一項公司股票購買交易。2024年8月29日,Gibson以每股2.48美元的價格購買了5,000股Recursion Pharmaceuticals的A類普通股。此次交易是衍生證券的行權或轉換的一部分。在此次收購之後,Gibson在公司的直接持股增加到總共757,656股。該交易目前正在進行中。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息